The DOI matches its Crossref record.
Prediction of Doxorubicin Resistance In Vitro in Myeloma, Lymphoma, and Breast Cancer by P-Glycoprotein Staining
Abstract
Prior studies have shown that the P-glycoprotein is a cell membrane efflux pump that is quantitatively increased in expression in multidrug-resistant tumor cell lines. In this study, fresh tumor tissues from patients with multiple myeloma, malignant lymphoma, or metastatic breast cancer were studied immunohistochemically for P-glycoprotein expression and for in vitro sensitivity to doxorubicin. Twenty-six patients who were either previously untreated or in relapse after chemotherapy had tumor specimens submitted that could be evaluated in both assays. The testing was done independently and blindly in separate laboratories instead of our being provided relevant clinical data on the patients. Tumor cells from 12 of the 26 patients (46%) stained positively for P-glycoprotein. Fifteen of the 26 specimens (58%) exhibited drug resistance in vitro. Although only three (21%) of the 14 P-glycoprotein-negative tumors exhibited in vitro resistance to doxorubicin, all 12 fresh tumors that stained positively for P-glycoprotein were resistant to doxorubicin. The difference in frequency of intrinsic doxorubicin resistance between P-glycoprotein-negative and -positive tumors was highly significant (P less than .001). Similar trends were observed in each of the individual tumor categories and were statistically significant in myeloma and breast cancer. Four of the biopsy specimens that stained positively for P-glycoprotein and exhibited doxorubicin resistance were from patients who had not received prior cytotoxic chemotherapy. Similar conclusions were reached when results of drug sensitivity tests were ranked in relation to the median infective dose rather than by criteria based on correlations with clinical drug resistance. Our findings indicate that positive staining for P-glycoprotein associated with multidrug resistance predicts intrinsic cellular resistance of human cancers to doxorubicin. We anticipate that immunohistochemical staining for P-glycoprotein will prove useful in clinical oncology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Campos, L., Guyotat, D., Archimbaud, E., Calmard-Oriol, P., Tsuruo, T., Troncy, J., Treille, D., & Fiere, D. (1992) · Blood · doi:10.1182/blood.v79.2.473.473 · Cited by 487
Trock, B. J., Leonessa, F., & Clarke, R. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.917 · Cited by 434
Marie, J., Zittoun, R., & Sikic, B. (1991) · Blood · doi:10.1182/blood.v78.3.586.586 · Cited by 394
MDA435/LCC6 and MDA435/LCC6MDR1: ascites models of human breast cancer
Leonessa, F., Green, D., Licht, T., Wright, A., Wingate-Legette, K., Lippman, J., Gottesman, M., & Clarke, R. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.29 · Cited by 102
Metadata
- Authors
- Salmon, S. E., Grogan, T. M., Miller, T., Scheper, R., & Dalton, W. S.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 1989-05-03
- Volume
- 81
- Issue
- 9
- Pages
- 696-701
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2139330198
- Cited by
- 196
- References
- 0
- FWCI
- 11.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prediction of Doxorubicin Resistance In Vitro in Myeloma, Lymphoma, and Breast Cancer by P-Glycoprotein Staining. https://app.cochat.ai/papers/10.1093/jnci/81.9.696
- The paper
- Salmon, S. E., Grogan, T. M., Miller, T., Scheper, R., & Dalton, W. S. (1989). Prediction of Doxorubicin Resistance In Vitro in Myeloma, Lymphoma, and Breast Cancer by P-Glycoprotein Staining. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/81.9.696
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.